Advertisement

European Child & Adolescent Psychiatry

, Volume 23, Issue 10, pp 973–992 | Cite as

Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review

  • Hanan El Marroun
  • Tonya White
  • Frank C. Verhulst
  • Henning Tiemeier
Review

Abstract

Antidepressant and anxiolytic medications are widely prescribed and used by pregnant women for acute and maintenance therapy. These drugs are able to pass the placental barrier, and may potentially influence fetal and brain development. It is possible that exposure to prenatal antidepressants or anxiolytic medication may disturb neurotransmitter systems in the brain and have long-lasting consequences on neurodevelopment in the offspring. As all medication during pregnancy may pose a certain risk to the developing fetus, the potential benefits of the medication must be weighed against the risks for both mother and her unborn child. Therefore, information to guide patients and physicians to make a well-balanced decision for the appropriate treatment during pregnancy is needed. In this systematic review, an overview of maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes is provided. Some studies indicate a relation between prenatal exposure to antidepressants and adverse neurodevelopmental outcomes such as delayed motor development/motor control, social difficulties, internalizing problems and autism, but cannot rule out confounding by indication. Overall, the results of the observational studies have been inconsistent, which makes translation of the findings into clinical recommendations difficult. More well-designed observational studies and also randomized controlled trials (e.g., maintenance treatment vs. cessation) are needed to move forward and provide a comprehensive evaluation of the risks and benefits of antidepressant and anxiolytic use during pregnancy.

Keywords

Prenatal exposure Antidepressant medication Anxiolytic medication Child neurodevelopment 

Notes

Acknowledgments

We gratefully thank W.M. Bramer (professional librarian at the Erasmus MC) for his extensive assistance in the systematic literature searches.

The Sophia Children’s Hospital Fund (SSWO-616) supported this work financially. The Netherlands Organization for Scientific Research (NWO Brain and Cognition Program Grant 433-09-311 and VIDI Grant 017.106.370). The funding agencies had no role in the design and conduct of the study, collection, management, analyses and interpretation of the data; and preparation, review or approval of the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

787_2014_558_MOESM1_ESM.docx (155 kb)
Supplementary material 1 (DOCX 154 kb)

References

  1. 1.
    Melville JL, Gavin A, Guo Y, Fan MY, Katon WJ (2010) Depressive disorders during pregnancy: prevalence and risk factors in a large urban sample. Obstet Gynecol 116:1064–1070PubMedPubMedCentralGoogle Scholar
  2. 2.
    Ross LE, McLean LM (2006) Anxiety disorders during pregnancy and the postpartum period: a systematic review. J Clin Psychiatry 67:1285–1298PubMedGoogle Scholar
  3. 3.
    Vesga-Lopez O, Blanco C, Keyes K, Olfson M, Grant BF, Hasin DS (2008) Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry 65:805–815PubMedPubMedCentralGoogle Scholar
  4. 4.
    Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR (2004) Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 103:698–709PubMedGoogle Scholar
  5. 5.
    O’Hara MW, Swain AM (1996) Rates and risk of postpartum depression—a meta-analysis. Int Rev Psychiatry 8:37–54Google Scholar
  6. 6.
    Zuckerman B, Amaro H, Bauchner H, Cabral H (1989) Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol 160:1107–1111PubMedGoogle Scholar
  7. 7.
    Schetter CD (2011) Psychological science on pregnancy: stress processes, biopsychosocial models, and emerging research issues. Annu Rev Psychol 62:531–558Google Scholar
  8. 8.
    Goodman SH (2007) Depression in mothers. Annu Rev Clin Psychol 3:107–135PubMedGoogle Scholar
  9. 9.
    Goodman SH, Tully EC (2006) Depression in women who are mothers: an integrative model of risk for the development of psychopathology in their sons and daughters. In: Keyes CLM, Goodman SH (eds) Women and depression : a handbook for the social, behavioral, and biomedical sciences. Cambridge University Press, Cambridge, New York, pp 241–282Google Scholar
  10. 10.
    Goodman SH, Gotlib IH (1999) Risk for psychopathology in the children of depressed mothers: a developmental model for understanding mechanisms of transmission. Psychol Rev 106:458–490PubMedGoogle Scholar
  11. 11.
    Geddes J, Butler R, Hatcher S (2003) Depressive disorders. Clin Evid 9:1034–1057Google Scholar
  12. 12.
    El Marroun H, Jaddoe VW, Hudziak JJ, Roza SJ, Steegers EA, Hofman A, Verhulst FC, White TJ, Stricker BH, Tiemeier H (2012) Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry 69:706–714PubMedGoogle Scholar
  13. 13.
    Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653–661PubMedGoogle Scholar
  14. 14.
    Loughhead AM, Stowe ZN, Newport DJ, Ritchie JC, DeVane CL, Owens MJ (2006) Placental passage of tricyclic antidepressants. Biol Psychiatry 59:287–290PubMedGoogle Scholar
  15. 15.
    van der Aa EM, Peereboom-Stegeman JH, Noordhoek J, Gribnau FW, Russel FG (1998) Mechanisms of drug transfer across the human placenta. Pharmac World Sci: PWS 20:139–148Google Scholar
  16. 16.
    Rampono J, Simmer K, Ilett KF, Hackett LP, Doherty DA, Elliot R, Kok CH, Coenen A, Forman T (2009) Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 42:95–100PubMedGoogle Scholar
  17. 17.
    Levitt P, Harvey JA, Friedman E, Simansky K, Murphy EH (1997) New evidence for neurotransmitter influences on brain development. Trends Neurosci 20:269–274PubMedGoogle Scholar
  18. 18.
    Homberg JR, Schubert D, Gaspar P (2010) New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci 31:60–65PubMedGoogle Scholar
  19. 19.
    Olivier JD, Blom T, Arentsen T, Homberg JR (2011) The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: a review. Prog Neuropsychopharmacol Biol Psychiatry 35:1400–1408PubMedGoogle Scholar
  20. 20.
    Haas M, Qu Z, Kim TH, Vargas E, Campbell K, Petrou S, Tan SS, Reid CA, Heng J (2013) Perturbations in cortical development and neuronal network excitability arising from prenatal exposure to benzodiazepines in mice. Eur J Neurosci 37:1584–1593PubMedGoogle Scholar
  21. 21.
    Ross LE, Grigoriadis S, Mamisashvili L, Koren G, Steiner M, Dennis CL, Cheung A, Mousmanis P (2011) Quality assessment of observational studies in psychiatry: an example from perinatal psychiatric research. Int J Methods Psychiatr Res 20:224–234PubMedGoogle Scholar
  22. 22.
    Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52:377–384PubMedPubMedCentralGoogle Scholar
  23. 23.
    Wells GA, Shea B, O’Connell D, Petersen K, Welch V, Losos M, Tugwell P (2003) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In: Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, CanadaGoogle Scholar
  24. 24.
    Neal MJ (1997) Medical pharmacology at a glance. Blackwell Science, OxfordGoogle Scholar
  25. 25.
    Cooper WO, Willy ME, Pont SJ, Ray WA (2007) Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 196(544):e541–e545Google Scholar
  26. 26.
    Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Willy ME, Staffa JA, Platt R (2008) Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 198(194):e191–e195Google Scholar
  27. 27.
    Alwan S, Reefhuis J, Rasmussen SA, Friedman JM (2011) Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol 51:264–270PubMedGoogle Scholar
  28. 28.
    Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT (2008) Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 65:600–606PubMedPubMedCentralGoogle Scholar
  29. 29.
    Fenger-Gron J, Thomsen M, Andersen KS, Nielsen RG (2011) Paediatric outcomes following intrauterine exposure to serotonin reuptake inhibitors: a systematic review. Dan Med Bull 58:A4303PubMedGoogle Scholar
  30. 30.
    Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C (2006) Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 63:898–906PubMedGoogle Scholar
  31. 31.
    Ververs T, Kaasenbrood H, Visser G, Schobben F, De Jong-Van Den Berg L, Egberts T (2006) Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 62:863–870PubMedGoogle Scholar
  32. 32.
    Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, Nielsen RB, Norgaard M, Stephansson O, Valdimarsdottir U, Zoega H, Haglund B (2012) Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 344:d8012PubMedGoogle Scholar
  33. 33.
    Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Raebel MA, Roblin D, Smith DH, Yood MU, Morse AN, Platt R (2004) Prescription drug use in pregnancy. Am J Obstet Gynecol 191:398–407PubMedGoogle Scholar
  34. 34.
    Daw JR, Mintzes B, Law MR, Hanley GE, Morgan SG (2012) Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001–2006). Clin Ther 34(239–249):e232Google Scholar
  35. 35.
    Lacroix I, Hurault C, Sarramon MF, Guitard C, Berrebi A, Grau M, Albouy-Cossard C, Bourrel R, Elefant E, Montastruc JL, Damase-Michel C (2009) Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol 65:839–846PubMedGoogle Scholar
  36. 36.
    Lendoiro E, Gonzalez-Colmenero E, Concheiro-Guisan A, de Castro A, Cruz A, Lopez-Rivadulla M, Concheiro M (2013) Maternal hair analysis for the detection of illicit drugs, medicines, and alcohol exposure during pregnancy. Ther Drug Monit 35:296–304PubMedGoogle Scholar
  37. 37.
    Marchetti F, Romero M, Bonati M, Tognoni G (1993) Use of psychotropic drugs during pregnancy. A report of the international co-operative drug use in pregnancy (DUP) study. Collaborative Group on Drug Use in Pregnancy (CGDUP). Eur J Clin Pharmacol 45:495–501PubMedGoogle Scholar
  38. 38.
    Ornoy A, Arnon J, Shechtman S, Moerman L, Lukashova I (1998) Is benzodiazepine use during pregnancy really teratogenic? Reprod Toxicol 12:511–515PubMedGoogle Scholar
  39. 39.
    Palmsten K, Hernandez-Diaz S, Huybrechts KF, Williams PL, Michels KB, Achtyes ED, Mogun H, Setoguchi S (2013) Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ 347:f4877PubMedPubMedCentralGoogle Scholar
  40. 40.
    Gardarsdottir H, Heerdink ER, van Dijk L, Egberts AC (2007) Indications for antidepressant drug prescribing in general practice in the Netherlands. J Affect Disord 98:109–115PubMedGoogle Scholar
  41. 41.
    Olkkola KT, Ahonen J (2008) Midazolam and other benzodiazepines. Handb Exp Pharmacol 182:335–360Google Scholar
  42. 42.
    Sit DK, Perel JM, Helsel JC, Wisner KL (2008) Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry 69:652–658PubMedPubMedCentralGoogle Scholar
  43. 43.
    Little BB (1999) Pharmacokinetics during pregnancy: evidence-based maternal dose formulation. Obstet Gynecol 93:858–868PubMedGoogle Scholar
  44. 44.
    Whitaker-Azmitia PM, Druse M, Walker P, Lauder JM (1996) Serotonin as a developmental signal. Behav Brain Res 73:19–29PubMedGoogle Scholar
  45. 45.
    Represa A, Ben-Ari Y (2005) Trophic actions of GABA on neuronal development. Trends Neurosci 28:278–283PubMedGoogle Scholar
  46. 46.
    Lauder JM (1993) Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci 16:233–240PubMedGoogle Scholar
  47. 47.
    Brummelte S, Galea LA, Devlin AM, Oberlander TF (2013) Antidepressant use during pregnancy and serotonin transporter genotype (SLC6A4) affect newborn serum reelin levels. Dev Psychobiol 55:518–529PubMedGoogle Scholar
  48. 48.
    Bellissima V, Visser GH, Ververs TF, van Bel F, Termote JU, van der Heide M, Florio P, Volti GL, Gazzolo D (2011) Antenatal maternal antidepressants drugs affect Activin A concentrations in maternal blood, in amniotic fluid and in fetal cord blood. J Matern Fetal Neonatal Med 24(Suppl 2):31–34PubMedGoogle Scholar
  49. 49.
    Laugesen K, Olsen MS, Andersen ABT, Froslev T, Sorensen HT (2013) In utero exposure to antidepressant drugs and risk of attention deficit hyperactivity disorder: a nationwide Danish cohort study. BMJ Open 3:e003507PubMedPubMedCentralGoogle Scholar
  50. 50.
    Sorensen MJ, Gronborg TK, Christensen J, Parner ET, Vestergaard M, Schendel D, Pedersen LH (2013) Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin Epidemiol 5:449–459PubMedPubMedCentralGoogle Scholar
  51. 51.
    El Marroun H, White TJ, van der Knaap NJF, Homberg JR, Fernandez G, Schoemaker NK, Jaddoe VW, Hofman A, Verhulst FC, Hudziak JJ, Stricker BH, Tiemeier H (Accepted for publication) Prenatal exposure to SSRIs and social responsiveness symptoms of autism: a population-based study of young children. Br J PsychiatryGoogle Scholar
  52. 52.
    Pedersen LH, Henriksen TB, Bech BH, Licht RW, Kjaer D, Olsen J (2013) Prenatal antidepressant exposure and behavioral problems in early childhood—a cohort study. Acta Psychiatr Scand 127:126–135PubMedGoogle Scholar
  53. 53.
    Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C (2013) Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ 346:f2059PubMedPubMedCentralGoogle Scholar
  54. 54.
    Salisbury AL, Wisner KL, Pearlstein T, Battle CL, Stroud L, Lester BM (2011) Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment. Depress Anxiety 28:1008–1019PubMedPubMedCentralGoogle Scholar
  55. 55.
    Suri R, Hellemann G, Stowe ZN, Cohen LS, Aquino A, Altshuler LL (2011) A prospective, naturalistic, blinded study of early neurobehavioral outcomes for infants following prenatal antidepressant exposure. J Clin Psychiatry 72:1002–1007PubMedPubMedCentralGoogle Scholar
  56. 56.
    Warnock FF, Bakeman R, Shearer K, Misri S, Oberlander T (2009) Caregiving behavior and interactions of prenatally depressed mothers (antidepressant-treated and non-antidepressant-treated) during newborn acute pain. Infant Ment Health J 30:384–406Google Scholar
  57. 57.
    Weikum WM, Oberlander TF, Hensch TK, Werker JF (2012) Prenatal exposure to antidepressants and depressed maternal mood alter trajectory of infant speech perception. Proc Natl Acad Sci USA 109(Suppl 2):17221–17227PubMedPubMedCentralGoogle Scholar
  58. 58.
    Nulman I, Koren G, Rovet J, Barrera M, Pulver A, Streiner D, Feldman B (2012) Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry 169:1165–1174PubMedGoogle Scholar
  59. 59.
    Pedersen LH, Henriksen TB, Olsen J (2010) Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 125:e600–e608PubMedGoogle Scholar
  60. 60.
    Figueroa R (2010) Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. J Dev Behav Pediatr: JDBP 31:641–648PubMedGoogle Scholar
  61. 61.
    Kallen B (2004) Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 158:312–316PubMedGoogle Scholar
  62. 62.
    Kallen B, Reis M (2012) Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy. J Clin Psychopharmacol 32:608–614PubMedGoogle Scholar
  63. 63.
    Laegreid L, Hagberg G, Lundberg A (1992) Neurodevelopment in late infancy after prenatal exposure to benzodiazepines—a prospective study. Neuropediatrics 23:60–67PubMedGoogle Scholar
  64. 64.
    Mortensen JT, Olsen J, Larsen H, Bendsen J, Obel C, Sorensen HT (2003) Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics. Eur J Epidemiol 18:769–771PubMedGoogle Scholar
  65. 65.
    Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, Koren G (2002) Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 159:1889–1895PubMedGoogle Scholar
  66. 66.
    Gidai J, Acs N, Banhidy F, Czeizel AE (2008) An evaluation of data for 10 children born to mothers who attempted suicide by taking large doses of alprazolam during pregnancy. Toxicol Ind Health 24:53–60PubMedGoogle Scholar
  67. 67.
    Gidai J, Acs N, Banhidy F, Czeizel AE (2008) A study of the effects of large doses of medazepam used for self-poisoning in 10 pregnant women on fetal development. Toxicol Ind Health 24:61–68PubMedGoogle Scholar
  68. 68.
    Frisell T, Oberg S, Kuja-Halkola R, Sjolander A (2012) Sibling comparison designs: bias from non-shared confounders and measurement error. Epidemiology 23:713–720PubMedGoogle Scholar
  69. 69.
    Batton B, Batton E, Weigler K, Aylward G, Batton D (2013) In utero antidepressant exposure and neurodevelopment in preterm infants. Am J Perinatol 30:297–301PubMedGoogle Scholar
  70. 70.
    Austin MP, Karatas JC, Mishra P, Christl B, Kennedy D, Oei J (2013) Infant neurodevelopment following in utero exposure to antidepressant medication. Acta Paediatr, Int J PaediatrGoogle Scholar
  71. 71.
    Misri S, Reebye P, Kendrick K, Carter D, Ryan D, Grunau RE, Oberlander TF (2006) Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry 163:1026–1032PubMedGoogle Scholar
  72. 72.
    Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JGW, Kulin N, Koren G (1997) Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336:258–262PubMedGoogle Scholar
  73. 73.
    Boucher N, Bairam A, Beaulac-Baillargeon L (2008) A new look at the neonate’s clinical presentation after in utero exposure to antidepressants in late pregnancy. J Clin Psychopharmacol 28:334–339PubMedGoogle Scholar
  74. 74.
    Oberlander TF, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, Riggs W (2005) Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 115:411–425PubMedGoogle Scholar
  75. 75.
    Oberlander TF, Grunau RE, Fitzgerald C, Ellwood AL, Misri S, Rurak D, Riggs KW (2002) Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 51:443–453PubMedGoogle Scholar
  76. 76.
    Smith MV, Sung A, Shah B, Mayes L, Klein DS, Yonkers KA (2013) Neurobehavioral assessment of infants born at term and in utero exposure to serotonin reuptake inhibitors. Early Hum Dev 89:81–86PubMedPubMedCentralGoogle Scholar
  77. 77.
    de Vries NKS, van der Veere CN, Reijneveld SA, Bos AF (2013) Early neurological outcome of young infants exposed to selective serotonin reuptake inhibitors during pregnancy: results from the observational SMOK study. PLoS One 8(5):e64654Google Scholar
  78. 78.
    Casper RC, Gilles AA, Fleisher BE, Baran J, Enns G, Lazzeroni LC (2011) Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development. Psychopharmacology 217:211–219PubMedGoogle Scholar
  79. 79.
    Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, Hoyme HE (2003) Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 142:402–408PubMedGoogle Scholar
  80. 80.
    Galbally M, Lewis AJ, Buist A (2011) Developmental outcomes of children exposed to antidepressants in pregnancy. Aust N Z J Psychiatry 45:393–399PubMedGoogle Scholar
  81. 81.
    Klinger G, Frankenthal D, Merlob P, Diamond G, Sirota L, Levinson-Castiel R, Linder N, Stahl B, Inbar D (2011) Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. J Perinatol 31:615–620PubMedGoogle Scholar
  82. 82.
    Oberlander TF, Papsdorf M, Brain UM, Misri S, Ross C, Grunau RE (2010) Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Arch Pediatr Adolesc Med 164:444–451PubMedGoogle Scholar
  83. 83.
    Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V (2011) Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 68:1104–1112PubMedGoogle Scholar
  84. 84.
    Harrington RA, Lee LC, Crum RM, Zimmerman AW, Hertz-Picciotto I (2014) Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay. Pediatrics [Epub ahead of print]Google Scholar
  85. 85.
    Stika L, Elisova K, Honzakova L, Hrochova H, Plechatova H, Strnadova J, Skop B, Svihovec J, Vachova M, Vinar O (1990) Effects of drug administration in pregnancy on children’s school behaviour. Pharm Weekbl Sci 12:252–255PubMedGoogle Scholar
  86. 86.
    Laegreid L, Hagberg G, Lundberg A (1992) The effect of benzodiazepines on the fetus and the newborn. Neuropediatrics 23:18–23PubMedGoogle Scholar
  87. 87.
    Viggedal G, Hagberg BS, Laegreid L, Aronsson M (1993) Mental development in late infancy after prenatal exposure to benzodiazepines—a prospective study. J Child Psychol Psychiatry 34:295–305PubMedGoogle Scholar
  88. 88.
    Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM, National Birth Defects Prevention S (2007) Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356:2684–2692PubMedGoogle Scholar
  89. 89.
    Malm H, Artama M, Gissler M, Ritvanen A (2011) Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 118:111–120PubMedGoogle Scholar
  90. 90.
    Bakker MK, Kerstjens-Frederikse WS, Buys CH, de Walle HE, de Jong-van den Berg LT (2010) First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 88:94–100PubMedGoogle Scholar
  91. 91.
    Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA (2006) Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354:579–587PubMedGoogle Scholar
  92. 92.
    Lund N, Pedersen LH, Henriksen TB (2009) Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 163:949–954PubMedGoogle Scholar
  93. 93.
    Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL (1996) Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 335:1010–1015PubMedGoogle Scholar
  94. 94.
    Klieger-Grossmann C, Weitzner B, Panchaud A, Pistelli A, Einarson T, Koren G, Einarson A (2012) Pregnancy outcomes following use of escitalopram: a prospective comparative cohort study. J Clin Pharmacol 52:766–770PubMedGoogle Scholar
  95. 95.
    Jensen HM, Gron R, Lidegaard O, Pedersen LH, Andersen PK, Kessing LV (2013) Maternal depression, antidepressant use in pregnancy and Apgar scores in infants. Br J Psychiatry: J Ment Sci 202:347–351Google Scholar
  96. 96.
    Lim K, Sanders A, Brain U, Riggs W, Oberlander TF, Rurak D (2012) Third trimester fetal pulmonary artery Doppler blood flow velocity characteristics following prenatal selective serotonin reuptake inhibitor (SSRI) exposure. Early Hum Dev 88:609–615PubMedGoogle Scholar
  97. 97.
    Nijenhuis CM, ter Horst PG, van Rein N, Wilffert B, de Jong-van den Berg LT (2012) Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 2: testing the hypotheses. Br J Clin Pharmacol 73:126–134PubMedPubMedCentralGoogle Scholar
  98. 98.
    Davidson S, Prokonov D, Taler M, Maayan R, Harell D, Gil-Ad I, Weizman A (2009) Effect of exposure to selective serotonin reuptake inhibitors. In Utero on fetal growth: potential role for the IGF-I and HPA axes. Pediatr Res 65:236–241PubMedGoogle Scholar
  99. 99.
    Milkovich L, Van Den Berg BJ (1974) Effects of prenatal meprobamate and chlordiazepoxide hydrochloride on human embryonic and fetal development. N Engl J Med 291:1268–1271PubMedGoogle Scholar
  100. 100.
    Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR (1998) Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 317:839–843PubMedPubMedCentralGoogle Scholar
  101. 101.
    Gidai J, Acs N, Banhidy F, Czeizel AE (2010) Congenital abnormalities in children of 43 pregnant women who attempted suicide with large doses of nitrazepam. Pharmacoepidemiol Drug Saf 19:175–182PubMedGoogle Scholar
  102. 102.
    Calderon-Margalit R, Qiu C, Ornoy A, Siscovick DS, Williams MA (2009) Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am J Obstet Gynecol 201(579):e571–e578Google Scholar
  103. 103.
    Czeizel AE, Szegal BA, Joffe JM, Racz J (1999) The effect of diazepam and promethazine treatment during pregnancy on the somatic development of human offspring. Neurotoxicol Teratol 21:157–167PubMedGoogle Scholar
  104. 104.
    Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Suri R, Burt VK, Hendrick V, Reminick AM, Loughead A, Vitonis AF, Stowe ZN (2006) Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295:499–507PubMedGoogle Scholar
  105. 105.
    Verhamme K, Sturkenboom M (2011) Study designs in paediatric pharmacoepidemiology. Eur J Clin Pharmacol 67(Suppl 1):67–74PubMedGoogle Scholar
  106. 106.
    Wisner KL, Zarin DA, Holmboe ES, Appelbaum PS, Gelenberg AJ, Leonard HL, Frank E (2000) Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 157:1933–1940PubMedGoogle Scholar
  107. 107.
    Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W (2004) Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 65:230–237PubMedGoogle Scholar
  108. 108.
    Oberlander TF, Reebye P, Misri S, Papsdorf M, Kim J, Grunau RE (2007) Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med 161:22–29PubMedGoogle Scholar
  109. 109.
    Reebye PN, Ng TWC, Misri S, Stikarovska I (2012) Affect expression and self-regulation capacities of infants exposed in utero to psychotropics. Front Psychiatry 3Google Scholar
  110. 110.
    Oberlander TF, Grunau R, Mayes L, Riggs W, Rurak D, Papsdorf M, Misri S, Weinberg J (2008) Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. Early Hum Dev 84:689–697PubMedGoogle Scholar
  111. 111.
    Leibovitch L, Rymer-Haskel N, Schushan-Eisen I, Kuint J, Strauss T, Maayan-Metzger A (2013) Short-term neonatal outcome among term infants after in utero exposure to serotonin reuptake inhibitors. Neonatology 104:65–70PubMedGoogle Scholar
  112. 112.
    Weikum WM, Mayes LC, Grunau RE, Brain U, Oberlander TF (2013) The impact of prenatal serotonin reuptake inhibitor (SRI) antidepressant exposure and maternal mood on mother-infant interactions at 3 months of age. Infant Behav Dev 36:485–493PubMedGoogle Scholar
  113. 113.
    Weikum WM, Brain U, Chau CM, Grunau RE, Boyce WT, Diamond A, Oberlander TF (2013) Prenatal serotonin reuptake inhibitor (SRI) antidepressant exposure and serotonin transporter promoter genotype (SLC6A4) influence executive functions at 6 years of age. Front Cell Neurosci 7:180PubMedPubMedCentralGoogle Scholar
  114. 114.
    Galbally M, Lewis A, Lum J, Buist A (2009) Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust N Z J Psychiatry 43:846–854PubMedGoogle Scholar
  115. 115.
    Hale TW, Kendall-Tackett K, Cong Z, Votta R, McCurdy F (2010) Discontinuation syndrome in newborns whose mothers took antidepressants while pregnant or breastfeeding. Breastfeed Med 5:283–288PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Hanan El Marroun
    • 1
  • Tonya White
    • 1
    • 2
  • Frank C. Verhulst
    • 1
  • Henning Tiemeier
    • 1
    • 3
    • 4
  1. 1.The Department of Child and Adolescent PsychiatryErasmus MC, Sophia Children’s HospitalRotterdamThe Netherlands
  2. 2.The Department of RadiologyErasmus MCRotterdamThe Netherlands
  3. 3.The Department of PsychiatryErasmus MCRotterdamThe Netherlands
  4. 4.The Department of EpidemiologyErasmus MCRotterdamThe Netherlands

Personalised recommendations